viewLexaria Bioscience Corp.

Lexaria Bioscience granted two new US patents

The company announced Thursday it has been granted two new US patents related to cannabinoid infused beverage compositions

The new patents are related to certain cannabinoid infused beverage compositions

Lexaria Bioscience Corp. (OTCQX:LXRP, CSE:LXX), the drug delivery firm, announced Thursday it has been granted two new US patents.

The new patents are related to certain cannabinoid infused beverage compositions utilizing Lexaria's proprietary DehydraTECH process which continue to strengthen the company's intellectual property in the cannabis beverage market.

Lexaria now has six granted patents in the United States and four granted patents in Australia. 

Newly granted patent No. 10,103,225 and No. 10,084,044 provide protection for compositions as well as methods for making the compositions, each of which include the use of both non-psychoactive cannabinoids such as CBD and also psychoactive cannabinoids such as THC.

The company said it is currently pursuing accelerated examination for patent applications in Australia based on these newest U.S. patents and hopes to receive two corresponding Australian patents granted by the end of 2018.

The company said it has more than 50 patent applications filed worldwide across an increasingly diverse range of patent families. 

Shares of Lexaria were up 4.49% at C$2.28 on Thursday. 

Quick facts: Lexaria Bioscience Corp.

Price: 0.42 CAD

Market: CSE
Market Cap: $37.63 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...



Full interview: Lexaria Bio Science files patent for technology to treat...

Lexaria Bioscience (CSE: LXX-OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to discuss the company has filed a patent for their DehydraTech technology for the delivery of antiviral drugs. Bunka telling Proactive this technology would potentially be used to improve...

on 04/21/2020

2 min read